

09/26/2005 22:43 6102705253

GSK

PAGE 02/07

Docket No.: P51371

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"PROTEASE INHIBITORS"

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 August 2003  
and was amended on

as Serial No. PCT/US2003/026358  
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
--------	---------	-------------	------------------

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
60/405227	22 August 2002

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

- 2 -

Direct all correspondence to the address associated with Customer Number 20462.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: **William E. Bondinell**

Inventor's Signature: William E. Bondinell

Date: Feb 14, 2005

Residence: 1512 Franklin Lane, Wayne, PA 19087

Citizenship: United States

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: **Ralph E. Hall**

Inventor's Signature: Ralph E. Hall


Date: March 7, 2005

Residence: 709 Swedeland Road, King of Prussia, Pennsylvania

Citizenship: United States

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939


- 3 -

Full Name of Inventor: Qi JinInventor's Signature: Date: 03/04/05Residence: 709 Swedeland Road, King of Prussia, Pennsylvania

Citizenship: United States of America

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939


PA

Full Name of Inventor: Jeffrey K. KernsInventor's Signature: Date: 3/4/05Residence: 709 Swedeland Road, King of Prussia, Pennsylvania

Citizenship: United States of America

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

PA

Full Name of Inventor: Hong NieInventor's Signature: Date: 3/04/05Residence: 709 Swedeland Road, King of Prussia, Pennsylvania

Citizenship: United States of America

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

PA

- 4 -

Full Name of Inventor: Katherine L. Widdowson

Inventor's Signature: Kath Widdowson

Date: Mar 9, 2005

Residence: 709 Swedeland Road, King of Prussia, Pennsylvania PA

Citizenship: Canada

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

09/26/2005 22:43 6102705253

GSK

PAGE 07/07

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	10/525,114
	<b>Int Filing Date</b>	22 August 2003
	<b>First Named Inventor</b>	Bondinell
	<b>Title</b>	Protease Inhibitors
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	P51371

I hereby appoint:

☒ Practitioners associated with the Customer Numbers. 20462

Or

☐ Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:

Or

☒ The address associated with Customer Number 20462

Or

☐ Firm or Individual Name:

Address:

Address:

City:

State:

Zip:

Country:

Telephone:

Fax:

I am the:

☐ Applicant/Inventor:☒ Assignee or record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature:

Date: 27 September 2005

Name: Stephen Venetianer

Telephone: 610-270-5040

Title and Company: Vice President, Pharmaceuticals, SmithKline Beecham Corporation

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.

Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of: forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10/525114

09/26/2005 22:43 6102705253

GSK


PAGE 06/07

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>STATEMENT UNDER 37 CFR 3.73(b)</b>	
Applicant/Patent Owner: <b>SMITHKLINE BEECHAM CORPORATION</b>	
Application No./Patent No.: <b>10/525,114</b>	Int. Filed/Issue Date: <b>22 August 2003</b>
Entitled: <b>Protease Inhibitors</b>	
<b>SMITHKLINE BEECHAM CORPORATION, a corporation, states that it is:</b>	
1. <input checked="" type="checkbox"/> the assignee of the entire right, title, and interest; or	
2. <input type="checkbox"/> an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is _____ % in the patent application/patent identified above by virtue of either;	
A. <input checked="" type="checkbox"/> An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 015913, Frame 0979, or for which a copy thereof is attached.	
OR	
B. <input type="checkbox"/> A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
1. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
2. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
3. From: _____ To: _____ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.	
<input type="checkbox"/> Additional documents in the chain of title are listed on a supplemental sheet.	
<input type="checkbox"/> Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
 _____ Signature	27 September 2005_ _____ Date
<b>STEPHEN VENETIANER</b> _____ Printed or Typed Name	<b>610-270-5040</b> _____ Telephone Number
<b>Vice President, Pharmaceuticals</b> _____ Title	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.